Summit's lung-cancer drug ivonescimab fell short on survival data. Does the FDA approve it by its Nov 14 deadline?
100% of users predicted NO โ the community got this one right. 5 predictions cast.
The FDA declined to approve Summit Therapeutics' lung-cancer drug ivonescimab, issuing a complete response letter around its Nov. 14, 2026, target decision date rather than an approval. The application, developed with China's Akeso, covered ivonescimab for previously treated patients with EGFR-mutated non-small cell lung cancer. The FDA said the drug's Phase 3 HARMONi trial showed a progression-free survival benefit but did not demonstrate a statistically significant improvement in overall survival, and that a PFS benefit alone did not establish an adequate benefit-risk profile. Summit had reportedly been told before filing that the agency expected a significant survival benefit; an earlier analysis had put ivonescimab's overall survival hazard ratio at about 0.79, short of statistical significance. Summit said it would continue developing the drug, citing five positive Phase 3 studies across its and Akeso's programs and pointing to updated survival data it had submitted showing a consistent treatment effect across patient populations. The rejection was not a surprise to the prediction market: no forecaster had priced any chance of approval, reflecting the widely reported survival-data shortfall heading into the deadline. The setback also affects Akeso, as ivonescimab's PD-1xVEGF combination approach had been closely watched as a potential rival to existing checkpoint inhibitors such as Keytruda.